Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
NCT03673943
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
63
Enrollment
INDUSTRY
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
64Cu-DOTATATE
Sponsor
Radiomedix, Inc.